Free Trial
NASDAQ:CDIO

Cardio Diagnostics Q3 2025 Earnings Report

Cardio Diagnostics logo
$1.96 -0.04 (-2.00%)
Closing price 10/7/2026 03:59 PM Eastern
Extended Trading
$2.00 +0.04 (+2.24%)
As of 10/7/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics EPS Results

Actual EPS
-$0.98
Consensus EPS
-$1.80
Beat/Miss
Beat by +$0.82
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
$0.15 million
Beat/Miss
Missed by -$147.00 thousand
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cardio Diagnostics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules.

Conference Call Resources

Cardio Diagnostics Earnings Headlines

These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) is a biotechnology and medical technology company focused on the prevention and early detection of cardiovascular disease. The company combines artificial intelligence with genetic and epigenetic data to develop personalized tools intended to help identify cardiovascular risk and support more targeted care.

Its products include Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease, and PrecisionCHD, which is intended to help identify the presence of coronary heart disease. The company’s testing platform is designed to provide physicians with information that may support earlier intervention and individualized prevention strategies.

Founded in 2017, Cardio Diagnostics is headquartered in Chicago and serves the healthcare market through physician-ordered testing and related clinical services. The company was co-founded by Meesha Dogan, who has served as its chief executive officer, and uses its technology to address cardiovascular disease prevention and management.

View Cardio Diagnostics Profile